Kaplan Myron Form 4 October 01, 2018

#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**SECURITIES** 

Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

subject to Section 16. Form 4 or Form 5 obligations

Check this box

if no longer

Form 5
obligations
may continue.
See Instruction
1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

**OMB APPROVAL** 

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

(Print or Type Responses)

Stock

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Kaplan Myron Issuer Symbol CorMedix Inc. [CRMD] (Check all applicable) (First) (Middle) (Last) 3. Date of Earliest Transaction (Month/Day/Year) Director 10% Owner Other (specify Officer (give title C/O CORMEDIX INC., 400 10/01/2018 below) CONNELL DRIVE, SUITE 5000 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line)

#### BERKELEY HEIGHTS, NJ 07922

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of TransactionAcquired (A) or Security (Month/Day/Year) Execution Date, if Securities Form: Direct Indirect (Instr. 3) Code Disposed of (D) Beneficially (D) or Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Common 294,166 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

\_X\_ Form filed by One Reporting Person \_\_\_\_ Form filed by More than One Reporting

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: Kaplan Myron - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration I (Month/Day	Date	7. Title and Underlying S (Instr. 3 and	Securities
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	\$ 0	10/01/2018	10/01/2018	A	10,000	<u>(1)</u>	<u>(1)</u>	Common Stock	10,000
Stock Option (Right to Buy Common Stock)	\$ 0.57					(2)	02/16/2028	Common Stock	40,000
Restricted Stock Units	(3)					(3)	(3)	Common Stock	10,000
Restricted Stock Units	(3)					(3)	(3)	Common Stock	12,000
Restricted Stock Units	<u>(4)</u>					<u>(4)</u>	<u>(4)</u>	Common STock	5,000
Stock Option (Right to Buy Common Stock)	\$ 2.24					<u>(5)</u>	02/21/2027	Common Stock	40,000
Stock Option (Right to Buy Common Stock)	\$ 4.28					<u>(6)</u>	04/28/2026	Common Stock	50,000

## **Reporting Owners**

Reporting Owner Name / Address	Keiationsnips				
	Director	10% Owner	Officer	Other	

Reporting Owners 2

Kaplan Myron C/O CORMEDIX INC. 400 CONNELL DRIVE, SUITE 5000 BERKELEY HEIGHTS, NJ 07922

#### **Signatures**

a currently valid OMB number.

/s/ Alexander M. Donaldson, by power of attorney

10/01/2018

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units were granted on 10/01/2018 for service on the Company's Strategic Finance Committee. Each restricted stock (1) unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest monthly and will vest in full on the first anniversary of the date of grant, subject to continued service on the board.
- (2) These options were granted on 2/16/2018. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
- These Restricted Stock Units were granted on 2/16/2018. Each restricted stock unit represents the right to receive one share of CorMedix (3) Inc. common stock. The restricted stock units vest in full on the first anniversary of the date of grant, subject to continued service on the board
- The restricted stock units were granted on 11/6/2017. Each restricted stock unit represents the right to receive one share of CorMedix Inc.
- (4) common stock. The restricted stock units vest in full on the first anniversary of November 6, 2017, subject to continued service on the board
- (5) These options were granted on 2/21/2017. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
- (6) These options were granted on 4/28/2016. These options shall vest as follows: 1/3 on 4/28/2016, 1/3 on 4/28/2017, and 1/3 on 4/28/2018. Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays

Signatures 3